Research graph
References from MEK inhibition achieves robust and durable responses in Erdheim–Chester disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Erdheim–Chester disease: a rapidly evolving disease model
10.1038/s41375-020-0944-4 · 2020 · External reference
Erdheim–Chester disease
10.1182/blood.2019002766 · 2020 · External reference
Erdheim–Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
10.1182/blood.2019003507 · 2020 · External reference
Cluster analysis reveals the clinical spectrum of Erdheim–Chester disease
10.1038/s41375-025-02656-w · 2025 · External reference
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)‐mutated Erdheim–Chester disease
10.1200/jco.2014.57.1950 · 2015 · External reference
Targeted therapies in 54 patients with Erdheim–Chester disease, including follow‐up after interruption (the LOVE study)
10.1182/blood-2017-03-771873 · 2017 · External reference
Efficacy of MEK inhibition in patients with histiocytic neoplasms
10.1038/s41586-019-1012-y · 2019 · External reference
MEK inhibitors are effective in Erdheim–Chester disease regardless of MAPK pathway mutations
10.1038/s41375-025-02614-6 · 2025 · External reference
Long‐term outcomes with single‐agent BRAF inhibitor therapy in Erdheim–Chester disease
10.1182/blood.2024028032 · 2025 · External reference
Real‐life efficacy and safety of BRAF inhibitors in Erdheim–Chester disease
10.1002/ajh.70137 · 2026 · External reference
Declaration of Helsinki: ethical principles for medical research involving human subjects
10.1001/jama.2013.281053 · 2013 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
From RECIST to PERCIST evolving considerations for PET response criteria in solid tumors
10.2967/jnumed.108.057307 · 2009 · External reference
Long‐term follow‐up of mTOR inhibition for Erdheim–Chester disease
10.1182/blood.2019004478 · 2020 · External reference
Childhood‐onset Erdheim–Chester disease in the molecular era: clinical phenotypes and long‐term outcomes of 21 patients
10.1182/blood.2023020569 · 2023 · External reference
Long‐term outcome and prognosis of mixed histiocytosis (Erdheim–Chester disease and Langerhans cell histiocytosis)
10.1016/j.eclinm.2024.102658 · 2024 · External reference
Unresolved reference
External reference
Cardiovascular involvement, an overlooked feature of Erdheim–Chester disease: report of 6 new cases and a literature review
10.1097/01.md.0000145368.17934.91 · 2004 · External reference
Erdheim–Chester disease. Clinical and radiologic characteristics of 59 cases
10.1097/00005792-199605000-00005 · 1996 · External reference
Successful treatment of non‐Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
10.1182/bloodadvances.2022009013 · 2023 · External reference
Efficacy of MEK inhibitors in Erdheim–Chester disease: impact of MAPK pathway pathogenic variants
10.1038/s41375-025-02526-5 · 2025 · External reference
Histiocytosis and the nervous system: from diagnosis to targeted therapies
10.1093/neuonc/noab107 · 2021 · External reference
Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: results from the European Consortium for Histiocytosis
10.1002/hem3.70392 · 2026 · External reference
Role of clonal inflammatory microglia in histiocytosis‐associated neurodegeneration
10.1016/j.neuron.2025.02.007 · 2025 · External reference
Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
10.18632/oncotarget.24696 · 2018 · External reference
Impact of drug–drug interactions on clinical outcomes in metastatic melanoma patients treated with combined BRAF/MEK inhibitors: a real‐world study
10.1111/pcmr.70026 · 2025 · External reference
Prevalence, patterns and outcomes of cardiac involvement in Erdheim–Chester disease
10.1093/eurheartj/ehac741 · 2023 · External reference
Clinical phenotypes and long‐term outcome of kidney involvement in Erdheim–Chester histiocytosis
10.1016/j.kint.2022.09.027 · 2023 · External reference
Anakinra improves retention rate of targeted treatments in Erdheim–Chester disease
10.1093/rheumatology/keaf023 · 2025 · External reference
Treatment holidays in patients with Erdheim–Chester disease receiving vemurafenib: a prospective pilot study
10.1182/bloodadvances.2024015399 · 2025 · External reference
